Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases.
about
sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportinMechanisms and regulation of iron trafficking across the capillary endothelial cells of the blood-brain barrierPharmacology of iron transportAlzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasisInflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cellsSynthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholA nuclear factor-binding domain in the 5'-untranslated region of the amyloid precursor protein promoter: implications for the regulation of gene expression.The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.Global signatures of protein and mRNA expression levels.Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1.β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin.Gender and iron genes may modify associations between brain iron and memory in healthy aging.Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men.Deferoxamine attenuates lipopolysaccharide-induced neuroinflammation and memory impairment in mice.Infectious prion protein alters manganese transport and neurotoxicity in a cell culture model of prion disease.The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expressionGenomic Characteristics of Genetic Creutzfeldt-Jakob Disease Patients with V180I Mutation and Associations with Other Neurodegenerative Disorders.Curcumin: a natural substance with potential efficacy in Alzheimer's disease.A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD.Metal ion physiopathology in neurodegenerative disorders.Using NMR chemical shifts to calculate the propensity for structural order and disorder in proteins.Disruption of zinc homeostasis and the pathogenesis of senile dementia.Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease.Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's diseaseCross talk between neurometals and amyloidogenic proteins at the synapse and the pathogenesis of neurodegenerative diseases.Translational repression of the disintegrin and metalloprotease ADAM10 by a stable G-quadruplex secondary structure in its 5'-untranslated region.Repositioning drugs for traumatic brain injury - N-acetyl cysteine and PhenserineEGCG Protects against 6-OHDA-Induced Neurotoxicity in a Cell Culture Model.Amyloid and Alzheimer's disease.Modulation of iron metabolism in aging and in Alzheimer's disease: relevance of the choroid plexusIron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases.Identification of CD300a as a new hypoxia-inducible gene and a regulator of CCL20 and VEGF production by human monocytes and macrophages.α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice.Alpha-synuclein, proteotoxicity and Parkinson's disease: Search for neuroprotective therapy.Glial amyloid precursor protein expression is restricted to astrocytes in an experimental toxic model of multiple sclerosis.Detection of glycosylation and iron-binding protein modifications using Raman spectroscopy.Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse.Iron and Alzheimer's Disease: From Pathogenesis to Therapeutic ImplicationsImplications of Metal Binding and Asparagine Deamidation for Amyloid Formation
P2860
Q24298395-23042A4E-7DE6-4DBE-BE47-071227977E0CQ26800099-6A0D82E3-0AE3-4E8F-9B3B-0B426542C514Q27009387-B94AFF51-EB86-4BD5-BA1E-5EA7BF4768DCQ27024824-6B694F99-8352-43D6-88DD-0C38EF33C55AQ28572077-D697231C-9D4F-48C5-AF34-4AF529B29DE3Q28818062-7500F2A6-7876-457F-8639-6CF870142A29Q33537445-18CFC086-3985-4ABB-9D9F-8387437358E5Q33790013-D5347132-DF02-47E5-94F0-21542B9FDAD9Q33874396-2BF9C748-BC01-4D93-9464-CC53CA99FA56Q34181256-67118102-1B86-4104-8430-2E1FEF618B0AQ34612398-D835DC6B-3703-4DF8-9C7B-810529A86D20Q34988395-B6B8851B-8E61-475B-800E-E22CD64CC576Q35057484-C601D8BF-F879-4B9E-A4E5-5BFB01A41C0EQ35068436-D66981B0-445C-4984-B7D6-C4355CE5EDD2Q35499246-EA7913F7-F90B-43DF-A6F5-676C90AC32C4Q36012226-BC129E5F-B1B4-4AE6-8CA4-F7D3742A7B02Q36060992-EF70929C-B4A2-4C32-B903-596C452F66E6Q36891064-B1D9F132-6C71-41D4-9C17-FC60C8C29610Q37258755-0D950F45-A11B-4E96-A089-FB4EC4BB71A7Q37641152-69E6108E-CA14-451B-9FAD-078917115B86Q38044420-8C10716C-9618-421E-A83E-AB7A9375716EQ38163821-E8EC4224-0FA4-4762-B963-FB40A5F7289CQ38186783-9C21758C-7FB5-4B9D-BB01-DB52F87ECBCCQ39205712-BB0920B8-E6A9-4ABF-9567-56CF2EEFFE42Q39314484-34208526-C097-4907-8D1A-B1CDD1CBE16BQ40041919-085B2C36-C278-4531-98C3-DE8E0E77810DQ41467872-299A6CFA-831C-4B22-979F-E7F4838D6806Q42114369-CB9D12EF-085D-43B5-BAF1-375AD42C5FDFQ42138218-DF19754D-4763-4B24-AB52-3723710576E2Q42149893-00858524-9034-46D6-BF1D-09C779E213CEQ42643645-67920AA8-9EFD-4698-9E4A-3840CEEE1C4EQ44759466-D60C522F-4793-475A-A1BA-F274F7EAF4AFQ44893565-84B97765-853A-4ACB-B958-D3B706FEE829Q47348189-767F32B1-39A6-43DE-AAEC-96767DC96F07Q48137910-86931075-5A92-43E7-A67C-A11854F8F0BCQ48264659-F2C6C5E2-916E-4CF6-AB27-0C63B3D3BCE7Q55418661-CEF83BC6-F161-4A0A-B58C-EE25EE7A6910Q58754278-0130F5F8-7711-4695-973A-8BBB74E7090AQ58765987-9015653C-63B5-4BBA-9FAD-EBB3559E3C9D
P2860
Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Amyloid precursor protein and ...... in neurodegenerative diseases.
@en
Amyloid precursor protein and ...... in neurodegenerative diseases.
@nl
type
label
Amyloid precursor protein and ...... in neurodegenerative diseases.
@en
Amyloid precursor protein and ...... in neurodegenerative diseases.
@nl
prefLabel
Amyloid precursor protein and ...... in neurodegenerative diseases.
@en
Amyloid precursor protein and ...... in neurodegenerative diseases.
@nl
P2093
P2860
P921
P1476
Amyloid precursor protein and ...... in neurodegenerative diseases.
@en
P2093
Catherine M Cahill
Debomoy K Lahiri
Jack T Rogers
Xudong Huang
P2860
P304
P356
10.1016/J.BBAGEN.2008.12.001
P407
P577
2008-12-29T00:00:00Z